FFG Austrian Life Sciences
Supports Austrian life-science innovation in digital health, drug development, and medical technologies.
The Austrian Life Sciences 2024–2026 call funds Austrian company-led R&D and clinical studies in life sciences. Eligible focus areas are digitalization with health aspects (diagnostics, telemedicine, medical devices), new drugs and medical devices, and interventional phase I and II clinical studies. Participation along the entire value chain is required; foreign partners may participate depending …
Digitalization with health aspects; new drugs and medical devices; planning and implementation of interventional phase I and II clinical studies.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline